Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer-Reference-Cited by-同舟云学术

Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer

Published:2022-01 Issue:1 Volume:42 Page:17-36
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Cheng Bo¹²,Ding Kaikai³²,Chen Pengxiang⁴,Ji Jianxiong³²⁵,Luo Tao³²,Guo Xiaofan³⁶,Qiu Wei³²,Ma Chunhong⁷,Meng Xue¹,Wang Jian³²⁸,Yu Jinming¹^ORCID,Liu Yuan⁴²^ORCID

Affiliation:

1. Department of Radiation Oncology Shandong Cancer Hospital and Institute Cheeloo College of Medicine Shandong University Jinan Shandong 250012 P. R. China

2. Shandong Key Laboratory of Brain Functional Remodeling Jinan Shandong 250012 P. R. China

3. Department of Neurosurgery Qilu Hospital of Shandong University Cheeloo College of Medicine Shandong University Jinan Shandong 250012 P. R. China

4. Department of Radiation Oncology Qilu Hospital of Shandong University Cheeloo College of Medicine Shandong University Jinan Shandong 250012 P. R. China

5. Department of Neurosurgery the Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310000 P. R. China

6. Department of Neurology Loma Linda University Health Loma Linda CA 92354 USA

7. Key Laboratory for Experimental Teratology of Ministry of Education and Department of Immunology Shandong University School of Medicine Jinan Shandong 250012 P. R. China

8. Department of Biomedicine University of Bergen Bergen 5009 Norway

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12244

Reference37 articles.

1. Cancer statistics, 2019

2. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

3. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

4. Merck Announces Update on the INTR@PID Clinical Program Including Lung 037 Study. Available from:https://www.merckgroup.com/en/news/bintrafusp‐alfa‐037‐update‐20‐01‐2021.html.

5. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming growth factor-β micro-environment mediated immune cell functions in cervical cancer;International Immunopharmacology;2024-10

2. Therapeutic targeting of TGF‐β in lung cancer;The FEBS Journal;2024-07-31

3. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial;Cancer Cell;2024-07

4. Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer;Frontiers in Medicine;2024-05-22

5. Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective;Pharmaceuticals;2024-04-20